Clinical Trials Browser

Breast Neoplasms × tucatinib × 90 days × Clear all

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05132582 2026-03-16

HER2CLIMB-05

Phase 3 Active not recruiting

654 enrolled

Breast

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05382364 2026-03-12

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Phase 1 Active not recruiting

25 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT07193394 2026-02-23

H3RAKLES

Phase 2 Recruiting

20 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

81 enrolled

Breast

Breast Neoplasms

NCT05458674 2026-01-12

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT04721977 2026-01-09

MK-7119-001

Phase 2 Active not recruiting

66 enrolled 7 charts

Breast

Breast Neoplasms

NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

Completed

86 enrolled

Breast

Breast Neoplasms

Clinical Trials

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

HER2CLIMB-05

I-SPY

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

MK-1022-009

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

MK-7119-001

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.